-
Biotech/Pharma stocks News; BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review in Phase III Program
Tuesday, October 11, 2011 - 3:24pm | 1477LINCOLNSHIRE, Ill. - October 11, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study...
-
Biotech and Pharma Stock News; Aethlon Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation
Wednesday, October 5, 2011 - 11:46am | 1316SAN DIEGO - October 5, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier® and HER2osome™ cancer therapy will be the subject of a...
-
Pharma/Biotech Investor Alert; BioSante Trading Up Over 10% on News of Top LibiGel Efficacy Trial Results
Tuesday, October 4, 2011 - 2:41pm | 1239Point Roberts, WA; LINCOLNSHIRE, Ill - October 4, 2011 - Investorideas.com, a leader in sector stock research for independent investors , issues a trading alert for specialty biotech/ pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), following news released from the Company October 4th...
-
Biotech/Pharma stocks News; BioSante Pharmaceuticals, Inc. Completes Both Pivotal LibiGel® Efficacy Trials
Tuesday, October 4, 2011 - 2:15pm | 1359LINCOLNSHIRE, Ill. - October 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company's anticipated LibiGel new drug application (NDA). The final visit of...
-
Biotech and Pharma Stock Doubles During Monday's Trading Following Report of $6.8 Million DARPA Contract
Tuesday, October 4, 2011 - 12:06pm | 668Point Roberts, WA - October 4, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, reports Aethlon Medical (OTCBB: AEMD) stock traded up over 100% , as high as $0.12 in yesterday's trading session following news of a $6.8...
-
Biotech Stock Alert: Aethlon Medical Trading Up 50.88% on News of $6.8 million Contract from Defense Advanced Research Projects Agency
Monday, October 3, 2011 - 4:29pm | 587Point Roberts, WA - October 3, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, report Aethlon Medical (OTCBB: AEMD), a pioneer in developing therapeutic filtration devices is trading up at $0.0860, up 0.0290 (50.88%) on...
-
Biotech/Medical Technology Stock News; Aethlon Medical Receives Government Contract Award from DARPA
Monday, October 3, 2011 - 4:20pm | 975SAN DIEGO - October 3, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has been awarded a $6.8 million contract from the Defense Advanced Research...
-
Pharma and Biotech stocks News; BioSante Pharmaceuticals, Inc. To Present at Cancer Immunotherapy Conference
Monday, October 3, 2011 - 3:41pm | 604LINCOLNSHIRE, Ill. - October 3, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 6, 2011, at the New York Academy of Medicine in New York. The single-day conference...
-
Biotech Stock Alert; Aethlon Medical, ImmunoGen Report on HER2+ Breast Cancer Developments
Thursday, September 29, 2011 - 11:58am | 1013Point Roberts, WA - September 29, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks reports recent news and developments in HER2+ Breast Cancer treatment from Aethlon Medical (OTCBB: AEMD) and ImmunoGen (Nasdaq: IMGN)....
-
Biotech/Medical Technology Stock News; "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.
Tuesday, September 27, 2011 - 12:40pm | 584SAN DIEGO - September 27, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has released a white paper entitled: "A Medical Device Strategy To Inhibit...
-
Pharma/Biotech Stocks Reporting on Breast Cancer Treatments
Friday, September 23, 2011 - 1:15pm | 1073Point Roberts, WA - September 23, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues an update and recent news from Biotech, Pharma and Medical Technology stocks reporting on developments in the treatment of breast...
-
Biotech/Medical Technology Stock News; Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
Wednesday, September 21, 2011 - 1:58pm | 1333SAN DIEGO - September 21, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today the introduction of HER2osome™, a novel medical device strategy to inhibit the...
-
Biotech/Pharma Stocks to Watch: BioSante, RXi, Dendreon, Catalyst Pharmaceutical Partners
Tuesday, September 13, 2011 - 12:10pm | 1027POINT ROBERTS - September 13, 2001 - www.InvestorIdeas.com, a global investor research portal for independent investors issues a report for biotech and pharma stocks to watch based on trading and news for 12th September. U.S. markets ended higher after falling sharply earlier in the trading...
-
Biotech and Pharma News; BioSante Pharmaceuticals Successfully Completes LibiGel® Pharmacokinetic Study
Monday, September 12, 2011 - 12:25pm | 1466LINCOLNSHIRE, Ill. - September 12, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study. The top-line results indicate that LibiGel increases levels of free...
-
Biotech Investor Stock Alert; BioSante Trading its Way Back to $3.00
Friday, September 9, 2011 - 1:17pm | 1039Point Roberts, WA, LINCOLNSHIRE, Ill - September 9, 2011 - Investorideas.com, a leader in sector stock research for independent investors, issues a trading alert for specialty biotech/pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for the week of September 9th. The stock has bounced...